Immunovative Therapies
2 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Immunovative Therapies
Scoop.it!

Dr. Michael Har-Noy Discusses Curative Immunity in Cancer Therap

Dr. Michael Har-Noy discusses tumor avoidance in immunotherapy and introduces the Mirror EffectTM, a non-toxic mechanism that enable a patient’s own immune system to eradicate cancer cells.

Immunovative Therapies's insight:

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., a biotech company in Israel, says that harnessing the human immune system for effective cancer therapy has remained elusive to date in modern medical practice. The major limiting factor seems to be the cancer’s ability to avoid an attack by the patient’s immune system. Although tumors frequently elicit a strong immune response during their early growth, the immune response that is elicited is often suppressed by the tumor. Dr. Michael Har-Noy states that attempts to educate the patient’s immune response through cancer vaccines fail to stimulate anti-tumor immunity because they can’t overcome this ability of the tumor to suppress the immune response.

A person’s immune system is designed to destroy foreign proteins. However, says Dr. Michael Har-Noy, in the case of a normal pregnancy, the fetus is foreign to the mother, yet the mother’s immune cells do not destroy the fetus as they circulate in the fetal tissue. Dr. Michael Har-Noy says that the placenta sends out chemical signals which disable the immune cells that are programmed to kill foreign tissue. This is a completely natural immunosuppression mechanism.

Dr. Michael Har-Noy goes on to point out that cancers emit similar immunosuppressive chemical signals as those produced by a placenta. These chemicals neutralize attacks against the tumor, thereby allowing the tumor to grow unaffected by the patient’s immune system. This is the primary reason why cancer vaccines which attempt to educate the patient’s tumor-killing immune cells fail to eliminate the disease.

When immune and foreign cells mix, the array of chemicals that are released have the power to disable the immunosuppressive signals produced by tumors as well as a normal placenta. Dr. Michael Har-Noy indicates that this is why a transplanted immune system is so effective in eradicating a cancer. However, an immune system transplanted into a patient frequently attacks the patient’s normal tissues as well, creating a deadly side effect known as graft-versus-host disease (GVHD).

At Immunovative Therapies, Dr. Michael Har-Noy and his team have harnessed an immune response they have termed the Mirror EffectTM. The Mirror EffectTM stimulates a patient’s own immune system to attack foreign cancer cells. This response causes none of the toxicity of GVHD. Results of a preliminary Phase I/II trial suggest that Immunovative Therapies’ unique biologic compounds have anti-tumor activity against a wide variety of cancers and may, in the future, provide patients with curative immunity.

more...
No comment yet.
Scooped by Immunovative Therapies
Scoop.it!

Immunovative Therapies’ AlloStim™– A Unique Biologic Product For Treating Cance

Dr.Michael Har-Noy, founder and CEO of Immunovative Therapies, describes how AlloStim™ is produced from the blood of normal donors and, when infused into cancer patients, facilitates killing of the cancer by the patient’s own immune system.

Immunovative Therapies's insight:

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., a biotech company in Israel, has invented a unique compound, AlloStim™, which stimulates a patient’s own immune system to attack cancer cells. This enables a patient’s own immune system to potentially scavenge and eliminate every metastatic cell. AlloStim™ is produced from T-Stim cells, which are manufactured at Immunovative Therapies through proprietary, patented methods.

Dr. Michael Har-Noy describes T-Stim cells as being produced outside the body in a nine-day proprietary culture process (patents pending) in a bioreactor. T-Stim cells are produced from CD4+ CD45RA+ naïve T-cell precursors that are isolated from the blood of normal donors.  Characteristically, 100 million of these cells can be made from one normal person’s blood. After the nine-day culture process, approximately ten billion T-Stim cells can be manufactured.  There is no need to match donor to recipient as is necessary in bone marrow transplant procedures – AlloStim™ is intentionally mis-matched to the patient receiving it.

To manufacture T-Stim cells, Dr. Michael Har-Noy says that the naïve CD4 cells are cultured on a matrix coated with monoclonal antibodies. These monoclonal antibodies, namely anti-CD3 and anti-CD28, together with the cell-to-cell contact due to the high cellular density in the culture, causes activation, growth and maturation of the CD4 cells. The cells multiply at least 100-fold over the culture period, resulting in one normal donor producing enough T-Stim cells for about 100 patients.

At Immunovative Therapies, in this controlled environment, the T-Stim cells mature into memory CD4 cells that produce extremely high amounts of IL-2, IFN-g and TNF-a when activated. Also, T-Stim cells express high density CD40L and FasL on their cellular surface. CD40L interacts with the CD40 expressed on innate immune cells and stimulates these cells to manufacture Th1 cytokines that kill malignant cells. FasL enables these cells to kill tumors.

Dr. Michael Har-Noy adds that in order to produce the Mirror EffectTM, the name Immunovative Therapies has given to this unique method of immune system manipulation, the T-Stim cells require activation prior to infusion into the patient. T-Stim cells are activated with monoclonal antibody-coated particles that are then removed before infusion. “AlloStim™”  is the name given to activated, formulated T-Stim cells.

Dr. Michael Har-Noy indicates that Immunovative Therapies is preparing to test AlloStim™in a Phase II/III double-blind randomized trial of pre-treated metastatic breast cancer patients.

more...
No comment yet.